Biomed Valley Discoveries

Biotechnology, 4435 Main St Ste 550, City, Missouri, Kansas, 64111, United States, 11-50 Employees

Phone Number: 81********

Who is BIOMED VALLEY DISCOVERIES

Biomed Valley Discoveries, Inc. (BVD) is a clinical-stage biotechnology company on a quest to make a meaningful difference for patients and their families. HOPE FOR LIFE BVD is guided exc...

Get Full Access

Headquarters: 4435 Main St Ste 550, Kansas City, Missouri, 64111, United States
Date Founded: 2007
Employees: 11-50
Revenue: $1 Million to $5 Million
Active Tech Stack: See technologies

Industry: Biotechnology

SIC Code: 8733 | NAICS Code: 561110 | Show More

Does something look wrong? Fix it. | View contact records from BIOMED VALLEY DISCOVERIES

Biomed Valley Discoveries Org Chart and Mapping

Employees

Halle Zhang

Director of Translational Sciences, Project Leader

Email
Phone

Jessica Box

Senior Scientist, Translational Sciences

Email
Phone

David Tung

Senior Research Fellow

Email
Phone

See Full Org Chart

View Email Formats for Biomed Valley Discoveries

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding Biomed Valley Discoveries

Answer: Biomed Valley Discoveries's headquarters are located at 4435 Main St Ste 550, City, Missouri, Kansas, 64111, United States

Answer: Biomed Valley Discoveries, Inc. (BVD) is a clinical-stage biotechnology company on a quest to make a meaningful difference for patients and their families. HOPE FOR LIFE BVD is guided exclusively by our founders intent of bringing hope for life to patients. Our founders, Jim and Virginia Stowers, envisioned a biotech company that could approach the pursuit of groundbreaking medicines differently from the traditional biotech model. Jim Stowers founded the asset management firm, American Century Investments (ACI), which today manages over $200 billion in assets. Over 40% of annual profits from ACI are directed to the Stowers Group of Companies, including the Stowers Institute for Medical Research and BVD, providing a stable and sustainable source of funding to further scientific and clinical innovation. BIOTECH, PURPOSEFULLY REIMAGINED Our secure funding and our commitment to our founders intent have enabled us to build a purposefully reimagined biotech company, with distinct approaches to candidate sourcing, research and development, compassionate use/expanded access, collaborations, partnering/out-licensing, and overall corporate infrastructure. CURRENT PROGRAMS Our 3 novel oncology assets hold the potential to address significant unmet needs: -Ulixertinib, a highly selective, first-in-class ERK 1/2 inhibitor -TEM8 therapeutic antibodies, including TEM8-directed antibody drug conjugates (ADCs) -Clostridium novyi-NT, a cancer-fighting bacteria PARTNERING & OUT-LICENSING We are structured to take assets through early development to proof-of-concept. While we have the flexibility to advance niche/orphan disease programs through registration, our model is primarily centered around partnering and out-licensing our programs beyond this point. A prospective partner or out-licensee could be any organization with a vested interest in advancing a de-risked asset for a serious unmet medical need, from large or mid-size biopharma companies to venture capital firms.